Leef Brands, Inc.
LEEEF · Healthcare · $55.2M mkt cap · FY2025 filings · Shallow moat ·
Doesn't clear the bar
The five investor questions
2024–2025: revenue 28495447.00 to 34787596.00, increasing; diluted EPS -0.17 to -0.10, increasing. Two-year history is scoreable but carries less confidence than a full-cycle record.
Median gross margin 28.5% over 2y, very stable.
Not enough years of ROIC data to score returns on capital.
Net debt/EBITDA n/ax, interest coverage -3x.
Owner earnings trend unclear, share count growing (dilution).
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
Price vs. owner-earnings value range
- Owner earnings (normalized)
- —
- Value range / share
- —
- Conservative high estimate / share
- —
- Recent price
- $0.21
- Price vs. high estimate
- No price data
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
3 years of fundamentals
The business, in plain English
Leef Brands, Inc. booked $34.8M of revenue in FY2025 in the Healthcare sector and kept 30.1% of it as gross profit — a moderate-margin business by that measure. After every other cost, −50.7% of each revenue dollar reached the bottom line.
LEEEF's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Not disclosed in LEEEF’s filings for these years — we don’t estimate it.
Gaps in a line mean that item isn’t in LEEEF’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Healthcare context
#339 of 736 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #337NUWE Nuwellis, Inc.41.8 out of 100, Shallow moatShallow moat
- #338MRNA Moderna, Inc.41.8 out of 100, Shallow moatShallow moat
- #340ATPC AGAPE ATP CORPORATION41.8 out of 100, Shallow moatShallow moat
- #341UPB UPSTREAM BIO, INC.41.7 out of 100, Shallow moatShallow moat
Compare LEEEF with its nearest peers →All Healthcare companies on the Index →
Common questions about LEEEF
- Does Leef Brands, Inc. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores Leef Brands, Inc. (LEEEF) 41.8 out of 100 — a Shallow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 70, pricing power 46, returns on capital not measurable from the filings, balance-sheet safety 28, capital discipline 24.
- How has LEEEF's Moat Score changed over time?
- The record logs 5 readings since Jul 18, 2026; the latest reads 41.8 out of 100 (shallow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.